Article Text

Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis
  1. I. Wagner, DVM1,
  2. K. J. Geh, pharmacist2,
  3. M. Hubert, pharmacist, PhD2,
  4. G. Winter, pharmacist, Prof2,
  5. K. Weber, DVM, PD1,
  6. J. Classen, DVM1,
  7. C. Klinger, DVM1 and
  8. R. S. Mueller, Prof, DVM, DipECVD, DipACVD, FANZCVS1
  1. 1Clinic of Small Animal Medicine, Center for Clinical Veterinary Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany
  2. 2Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, LMU Munich, Butenandtstrasse 5, 81377 Munich, Germany
  1. E-mail for correspondence: iriswagner{at}


Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.

  • Allergy
  • Atopy
  • Dogs
  • Immunomodulation
  • TLR9

Statistics from


  • Provenance Not commissioned; externally peer reviewed.

  • Preliminary results were presented as an Abstract at the 24th annual Congress of Internal Medicine and Clinical Laboratory Diagnostics of the German Association of Veterinary Medicine (Deutsche Veterinärmedizinische Gesellschaft), Berlin, 29–30 January 2016 and at the Congress of the European Academy of Allergy and Clinical Immunology, Vienna, 11–15 June 2016.

  • Competing interests None declared.

  • Funding This study was supported by a grant from the Society for Advancement of Cynologic Research (Gesellschaft zur Förderung Kynologischer Forschung e.V., GKF)i. The GKF played no role in the study design nor in the collection, analysis and interpretation of data, nor in the decision to submit the manuscript for publication.

  • i

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.